Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
2026: prohibited at all times (S2). [1]
2026 List, S2.2.3, printed page 8 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
Identity and medical context
AOD-9604 is a synthetic 16-amino-acid peptide based on the end of human growth hormone with an additional tyrosine. It is not interchangeable with full-length growth hormone. FDA separately assesses its free-base and acetate forms. [2]
Weight-loss evidence
FDA’s review describes the company-reported OPTIONS trial: 502 adults with obesity were randomized in a blinded, placebo-controlled oral study lasting 24 weeks, alongside diet and exercise measures. The primary 12-week weight-loss comparison was not significant. The underlying full trial report was not independently obtained, so this account is a regulator’s assessment of submitted material, not a fresh analysis of the trial data. [2]
- Oral obesity results cannot validate injected preparations, other populations or advertised recovery benefits.
Safety and exposure
FDA identifies limited long-term safety information and concerns about peptide impurities, aggregation and immune reactions. Its review describes oral and injectable wellness-market products; this is marketing evidence, not confirmation of any current product’s contents. The staff assessment is not itself a final legal determination or product approval. [2]
What remains uncertain
- No independently readable primary OPTIONS publication was obtained.
- No product-specific assay or basis for a safe dose was established.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Effective date; S0 printed page 4; S2 printed pages 7–8
- FDA staff review: AOD-9604, 5 November 2024 ↗Accessed 2026-11-10 · official_full_text_relevant_sections
Identity; effectiveness; OPTIONS study; safety and product marketing
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.